Haima Therapeutics

Haima Therapeutics is a preclinical-stage biopharmaceutical company dedicated to developing cell-inspired therapies for the treatment of bleeding and various blood-related disorders. Haima’s initial focus is on platelet-inspired therapies to mitigate active bleeding and bleeding risks following traumatic injuries, surgeries, thrombocytopenia, and rare bleeding disorders. Its leading technology, called SynthoPlate, is a novel fully synthetic hemostatic agent that reduces bleeding by targeting the site of injury and enhancing the body's natural clotting mechanisms.